NCT04964505 2026-02-23
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
University of California, Davis
Phase 1 Terminated
Clinical Trials
7 trialsNCT03701308 2026-01-21
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT05146739 2025-11-12
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04839341 2025-06-27
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
Apollomics Inc.
Phase 1 Completed
NCT05569512 2024-08-19
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT04682405 2023-12-15
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Washington University School of Medicine
Phase 2 Completed
NCT02306291 2019-05-17
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
GlycoMimetics Incorporated
Phase 1/2 Completed